Cargando…

Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial

BACKGROUND/AIMS: Minimal hepatic encephalopathy (MHE) implies subtle impairment of cognitive functions in the absence of features of overt encephalopathy. We aimed to determine the prevalence of MHE in patients with liver cirrhosis and to find out the effect of rifaximin, probiotics, and l-ornithine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Kapil, Pant, Sanjay, Misra, Sriprakash, Dwivedi, Manisha, Misra, Alok, Narang, Sushil, Tewari, Reshu, Bhadoria, Ajeet S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131305/ https://www.ncbi.nlm.nih.gov/pubmed/25038208 http://dx.doi.org/10.4103/1319-3767.136975

Ejemplares similares

Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
por: Kircheis, Gerald, et al.
Publicado: (2019)

Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs
por: Ahn, Jin-Ok, et al.
Publicado: (2016)

l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
por: Butterworth, Roger F., et al.
Publicado: (2019)

Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis
por: Butterworth, Roger F.
Publicado: (2019)

Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats
por: Najmi, Abul K., et al.
Publicado: (2010)

Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis
por: Horvath, Angela, et al.
Publicado: (2022)

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
por: Pichon, Camille, et al.
Publicado: (2022)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle
por: Butterworth, Roger F.
Publicado: (2019)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease
por: Canbay, Ali, et al.
Publicado: (2019)

L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson’s Disease Models
por: Sisalli, Maria Josè, et al.
Publicado: (2022)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Bipolar Membrane Electrodialysis for Direct Conversion of L-Ornithine Monohydrochloride to L-Ornithine
por: He, Jinfeng, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy
por: Grover, Vijay P. B., et al.
Publicado: (2016)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
por: Safadi, Rifaat, et al.
Publicado: (2022)

Synthesis of L-Ornithine- and L-Glutamine-Linked PLGAs as Biodegradable Polymers
por: Taşkor Önel, Gülce
Publicado: (2023)

Hyperammonaemic Encephalopathy Caused by Adult-Onset Ornithine Transcarbamylase Deficiency
por: Niclasen, Bjarke Hammer, et al.
Publicado: (2022)

Acute Fulminant Encephalopathy in an Adult due to Ornithine Transcarbamylase Deficiency
por: Nambiar, Vivek K., et al.
Publicado: (2022)

L-Ornithine Derived Polyamines in Cystic Fibrosis Airways
por: Grasemann, Hartmut, et al.
Publicado: (2012)

Blood–brain barrier dysfunction in l-ornithine induced acute pancreatitis in rats and the direct effect of l-ornithine on cultured brain endothelial cells
por: Walter, Fruzsina R., et al.
Publicado: (2022)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_svorncepomrjq9tlq47m4s339a